Skip to content

Mounjaro vs Trulicity: uses, doses, cost and the one head-to-head trial

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Mounjaro vs Trulicity compares Eli Lilly's two once-weekly injections for type 2 diabetes in adults and children 10 and older. Mounjaro is tirzepatide and Trulicity is dulaglutide. LillyDirect self-pay is $499 a month for Mounjaro and starts at $389 for Trulicity. In the cardiovascular trial on Mounjaro's label, Mounjaro was non-inferior to dulaglutide, and superiority was not established.

Source: LillyDirect self-pay

Key takeaways

  • Both are approved for blood sugar control in adults and children 10 and older with type 2 diabetes.
  • In the one direct trial, Mounjaro wasn't shown to be worse than dulaglutide on heart events, or better.
  • Paying cash through LillyDirect? Trulicity starts at $389 a month and Mounjaro is $499, at every strength.
  • Only Mounjaro has a savings card. It needs commercial insurance and excludes anyone on a government program.
  • No label turns a Trulicity dose into a Mounjaro dose. Your prescriber decides where you start and when.

Mounjaro vs Trulicity, side by side

From each FDA label and our verified price records
MounjaroTrulicity
Active ingredienttirzepatidedulaglutide
MakerEli Lilly and CompanyEli Lilly and Company
FDA-approved uses
  • adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus
  • reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who are at high risk for these events
  • adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus
  • reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors
How it is takenweekly (multi-dose pen); weekly (multi-dose vial); weekly (single-dose pen); weekly (single-dose vial)weekly (single-dose pen)
Strengths2.5 to 15 mg0.75 to 4.5 mg
Label starting dose
  • 2.5 mg weekly
  • 0.75 mg weekly
Cheapest verified self-pay$499 per fill at 15 mg
LillyDirect self-pay
$389 per fill at 4.5 mg
LillyDirect self-pay
With covering commercial insurance$25 with the manufacturer cardNo savings-card price listed
Medicare GLP-1 BridgeNoNo
LabelRevised: 8/2026 (DailyMed version 40)Revised: 3/2026 (DailyMed version 62)
Mounjaro: most common reactions on the label · Pool of two placebo-controlled trials in adults with type 2 diabetes (SURPASS-1 monotherapy and SURPASS-5 added to basal insulin with or without metformin); 718 patients exposed to Mounjaro for a mean of 36.6 weeks. Hypoglycemia is not included.
Reaction15 mgPlacebo
Nausea18%4%
Diarrhea17%9%
Decreased Appetite11%1%
Vomiting9%2%
Constipation7%1%
Dyspepsia5%3%
Trulicity: most common reactions on the label · Pool of placebo-controlled trials that included 1,670 adults with type 2 diabetes exposed to Trulicity 0.75 mg or 1.5 mg, with a mean duration of exposure of 23.8 weeks. Hypoglycemia is excluded.
Reaction1.5 mgPlacebo
Nausea21.1%5.3%
Vomiting12.7%2.3%
Diarrhea12.6%6.7%
Abdominal Pain9.4%4.9%
Decreased Appetite8.6%1.6%
Dyspepsia5.8%2.3%

Each table comes from that medicine's own trials. The trials differ in who was studied and for how long, so the percentages are not a head-to-head comparison.

Mounjaro and Trulicity are sibling products. Eli Lilly makes both, both treat type 2 diabetes with one injection a week, and both are sold through the same LillyDirect pharmacy. People usually land on this comparison because a prescriber has suggested moving from Trulicity to Mounjaro, or because a plan covers one and not the other. This page compares them using the FDA labels (Revised: 8/2026 (DailyMed version 40) for Mounjaro, Revised: 3/2026 (DailyMed version 62) for Trulicity) and our price records.

Mounjaro or Trulicity: which suits whom?

Start with what doesn’t separate them. Both are approved for blood sugar control in adults and in children 10 and older with type 2 diabetes, and both have a cardiovascular use in adults. The choice turns on other things.

  • You want one kind of pen and the lower cash price. Trulicity comes in one kind of pen with four strengths, and LillyDirect self-pay starts at $389 a month.
  • Your prescriber wants tirzepatide and your plan covers it, or you can use the savings card. That points to Mounjaro. Its LillyDirect self-pay price is $499 a month.
  • You’re asking about heart outcomes. A label trial compared the two directly and found Mounjaro non-inferior to dulaglutide (not shown to be worse), without establishing that it was superior.
  • You’re on Medicare. Both are Part D diabetes medicines, and neither is in the Medicare GLP-1 Bridge.

Which one is right for your blood sugar targets is a clinical question the labels don’t settle between them. If a move to Mounjaro has come up, ask your prescriber why, what you’d expect to change, and whether your plan will pay for it.

What is each approved for?

Mounjaro contains tirzepatide. Trulicity contains dulaglutide. Their first use is worded the same on both labels: alongside diet and exercise, to improve blood sugar control in adults and children 10 years of age and older with type 2 diabetes.

The cardiovascular uses differ in who they describe:

  • Mounjaro: adults with type 2 diabetes who are at high risk for major adverse cardiovascular events (serious heart and blood vessel events).
  • Trulicity: adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.

Neither is approved for weight management, and neither has been established as safe and effective in children under 10. The Trulicity label adds a caution for people with liver impairment, because clinical experience in that group is limited.

What did the head-to-head trial show?

Most comparisons on this site have to say that the trials were separate. This pair is an exception for one outcome.

The Mounjaro label reports SURPASS-CVOT, a cardiovascular outcomes trial with a median follow-up of 210.1 weeks in which the comparison drug was dulaglutide. Mounjaro was non-inferior to dulaglutide for major cardiovascular events, with a hazard ratio (how the rate of events compared between the two groups) of 0.92. Superiority was not established.

In plain words, the trial didn’t show Mounjaro to be worse than dulaglutide on those events, and it didn’t show it to be better. That’s all the direct evidence in our label records. The blood sugar trials in the Mounjaro and Trulicity guides used different patients and comparison treatments.

How do the pens and doses differ?

Device. Trulicity comes in one form, a single-dose pen in a carton of four. Mounjaro’s label lists four forms (single-dose pen, single-dose vial, KwikPen and multi-dose vial), and it asks prescribers to tell you which one you’ll get and make sure you’re trained on it. The KwikPen is not recommended for self-administration by children or by people who are visually impaired. Every Mounjaro price we hold is for the single-dose pen.

Doses. Mounjaro comes in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. Trulicity comes in 0.75 mg, 1.5 mg, 3 mg, 4.5 mg.

  • Mounjaro starts at 2.5 mg once weekly. If more blood sugar control is needed, the dose rises in 2.5 mg steps, each after at least 4 weeks, to a maximum of 15 mg in adults and 10 mg in children.
  • Trulicity starts at 0.75 mg once weekly. After 4 weeks it may be raised to 1.5 mg, then in 1.5 mg steps, each after at least 4 weeks, to a maximum of 4.5 mg in adults and 1.5 mg in children.

Both labels tie each increase to a need for more blood sugar control. Neither says the dose must go up. The milligrams aren’t comparable across the two medicines, and no label equates a Trulicity strength with a Mounjaro strength.

Missed doses. The rules point in different directions. Mounjaro: take the missed dose within 4 days (96 hours) after it was due, otherwise skip it. Trulicity: take it if at least 3 days (72 hours) remain before the next scheduled dose, otherwise skip it. If you move from one to the other, the rule you’ve learned changes. The missed dose tool handles both.

What does each cost?

Because one company sells both through the same channel, the prices are easy to set side by side:

  • LillyDirect self-pay. Mounjaro is $499 a month. Trulicity starts at $389 a month.
  • List price (the full price before any discount). Mounjaro is $1,112.16 per fill of four pens. Trulicity is $1,006.93 per month, also four pens.
  • A year of self-pay. Both are filled every 28 days, so a year is 13 fills: $6,487 for Mounjaro and $5,057 for Trulicity.

Each self-pay price is the same at every strength of that drug, so moving up a dose doesn’t change the monthly cost on either.

Mounjaro has a savings card for people with commercial drug insurance: as little as $25 a fill if the plan covers Mounjaro, and $499 a month if it doesn’t. The card excludes anyone on Medicare, Medicaid or another government program, and it expires on 12/31/2026.

The Mounjaro cost guide and Trulicity cost guide go through each route, the cost calculator prices a year, and the savings card guide compares the manufacturer cards.

Does insurance or Medicare cover them?

Commercial plans often list both, and many rank them. A common pattern is a preferred GLP-1 that must be tried before a plan pays for another, so your formulary (the plan’s list of covered drugs) may make the choice for you. Ask your plan which of the two is preferred, what tier (cost level) each is on, and whether prior authorization (the plan’s approval before it pays) is needed. If a request is denied, the appeal letter generator drafts a letter for your prescriber to adapt.

Medicare treats them alike. CMS states that type 2 diabetes is an indication eligible for Part D coverage, so both run through your Part D plan’s formulary, and your plan sets your share. Neither is among the drugs in the Medicare GLP-1 Bridge, which is for weight management and isn’t open to people with type 2 diabetes. The Medicare hub explains how the pieces fit.

How do the side effects compare?

Gastrointestinal (stomach and bowel) reactions lead both labels. The figures come from each drug’s own pool of placebo-controlled trials in adults with type 2 diabetes, which had different patients and lengths, so read each on its own terms.

Mounjaro (5 mg, 10 mg and 15 mg, versus placebo): nausea 12, 15 and 18 percent, versus 4 percent; diarrhea 12, 13 and 17 percent, versus 9 percent; vomiting 5, 5 and 9 percent, versus 2 percent.

Trulicity (0.75 mg and 1.5 mg, versus placebo): nausea 12.4 and 21.1 percent, versus 5.3 percent; diarrhea 8.9 and 12.6 percent, versus 6.7 percent; vomiting 6.0 and 12.7 percent, versus 2.3 percent.

Both labels warn that low blood sugar is more likely with insulin or a sulfonylurea (a type of diabetes medicine). In a trial of up to 104 weeks, hypoglycemia (glucose below 54 mg/dL) occurred in 13.8%, 9.9% and 12.8% of patients on Mounjaro 5 mg, 10 mg and 15 mg given with a sulfonylurea. In a 78-week trial, it occurred in 20% and 21% of patients on Trulicity 0.75 mg and 1.5 mg given with a sulfonylurea. Those are two different trials, not a comparison.

The boxed warning about thyroid C-cell tumors is on both labels. So is the same rule against use by people with a personal or family history of medullary thyroid carcinoma (a type of thyroid cancer) or with MEN 2 (an inherited condition linked to it).

Can you switch from Trulicity to Mounjaro?

The labels don’t script this move. The Mounjaro label gives no instructions for switching from another GLP-1 medicine and states only its starting dose of 2.5 mg once weekly. The Trulicity label likewise states only its 0.75 mg starting dose. No label table turns a Trulicity dose into a Mounjaro dose, and we don’t convert doses between drugs.

Your prescriber decides where you start and when you take the first dose of the new medicine. Our switching guides and the switching planner set out what each label says. Other pairings, such as Ozempic vs Trulicity, are on the comparison hub.

Frequently asked questions

Is Mounjaro better than Trulicity?

The one head-to-head result in our label records is on heart outcomes. In SURPASS-CVOT, with a median follow-up of 210.1 weeks, Mounjaro was non-inferior to dulaglutide (Trulicity) for major cardiovascular events, with a hazard ratio of 0.92, and superiority was not established. The labels' blood sugar trials were run separately, so they don't rank the two.

Is Mounjaro more expensive than Trulicity?

On the cash route, yes. LillyDirect self-pay is $499 a month for Mounjaro and starts at $389 a month for Trulicity, each the same at every strength. List prices are $1,112.16 per fill for Mounjaro and $1,006.93 per month for Trulicity. With insurance, your plan decides.

Can I switch from Trulicity to Mounjaro?

The Mounjaro label gives no instructions for switching from another GLP-1 medicine. It states only its starting dose, 2.5 mg once weekly. The Trulicity label is the same in reverse, with a 0.75 mg starting dose. No label converts between the two, so your prescriber decides the starting dose and timing.

Are Mounjaro and Trulicity both approved for children?

Yes. Both are approved to improve blood sugar control in children 10 years of age and older with type 2 diabetes. The maximum dose in children is 10 mg once weekly for Mounjaro and 1.5 mg once weekly for Trulicity. The Mounjaro label says its KwikPen is not recommended for self-administration by children.

Is there a savings card for Mounjaro and Trulicity?

Mounjaro has a savings card: as little as $25 a fill with commercial insurance that covers Mounjaro, or $499 a month if the plan doesn't cover it. It excludes government beneficiaries and expires 12/31/2026.

Sources (19)

  1. 1.
    FDA label (DailyMed): Mounjaro prescribing information, section 14.6
    “Over a median follow-up of 210.1 weeks, MOUNJARO was non-inferior to dulaglutide for reducing the occurrence of MACE-3. The estimated hazard ratio for time to first MACE was 0.92 (95.3% CI: 0.83, 1.01) for MOUNJARO compared to dulaglutide. Superiority to dulaglutide was not established.”
  2. 2.
    FDA label (DailyMed): Mounjaro prescribing information, section 2.2
    “MOUNJARO KwikPen is not recommended for self-administration by pediatric patients. MOUNJARO KwikPen is not recommended for self-administration by those who are visually impaired.”
  3. 3.
    FDA label (DailyMed): Mounjaro prescribing information, section 2.2
    “Inform patients and their caregiver(s) which MOUNJARO presentation (e.g., vial, pre-filled single-dose pen, single-patient-use KwikPen) they will receive and ensure they receive training appropriate for that specific presentation. If the prescribed MOUNJARO presentation changes, ensure patients and caregivers receive appropriate training and instruct them to consult the Instructions for Use for the newly prescribed presentation.”
  4. 4.
    FDA label (DailyMed): Mounjaro prescribing information, section 8.4
    “The safety and effectiveness of MOUNJARO have not been established in pediatric patients less than 10 years of age.”
  5. 5.
    FDA label (DailyMed): Mounjaro prescribing information, section 4
    “MOUNJARO is contraindicated in patients with: A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1)].”
  6. 6.
    FDA label (DailyMed): Mounjaro prescribing information, section 6.1
    “In an adult clinical trial up to 104 weeks of treatment, when administered with a sulfonylurea, hypoglycemia (glucose level <54 mg/dL) occurred in 13.8%, 9.9%, and 12.8%, and severe hypoglycemia occurred in 0.5%, 0%, and 0.6% of patients treated with MOUNJARO 5 mg, 10 mg, and 15 mg, respectively.”
  7. 7.
    FDA label (DailyMed): Trulicity prescribing information, section 2.1
    “The maximum recommended dosage is 4.5 mg injected subcutaneously once weekly.”
  8. 8.
    FDA label (DailyMed): Trulicity prescribing information, section 8.4
    “The safety and effectiveness of TRULICITY have not been established in pediatric patients less than 10 years of age.”
  9. 9.
    FDA label (DailyMed): Trulicity prescribing information, section 8.7
    “However, there is limited clinical experience in patients with mild, moderate, or severe hepatic impairment; therefore, use TRULICITY with caution in these patient populations.”
  10. 10.
    FDA label (DailyMed): Trulicity prescribing information, section 4
    “TRULICITY is contraindicated in patients with: Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1)].”
  11. 11.
    FDA label (DailyMed): Trulicity prescribing information, section 6.1
    “In a 78-week adult clinical trial, hypoglycemia (glucose level <54 mg/dL) occurred in 20% and 21% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with a sulfonylurea.”
  12. 12.
    CMS: Information for Part D Plans
    “Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. [...] If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
  13. 13.
  14. 14.
  15. 15.
  16. 16.
  17. 17.
  18. 18.
  19. 19.